__MAIN_TEXT__
feature-image

Page 1

2019

1399

20 –


-2019

2

2019 COVID-19

(

COVID-19

8

) .

–1 -2 -3 -4 -5 -6 -7 -8


3

-2019

-1 1425

19 800

.

-1 :

N95

-2

). (98 -3 (98

). -4 (98

). -5 (98

(

)

):

52

9 .(99

-

). 2

-

.(99 32 .( .(98 .(98

) )

) 5

-

7

-

5

-

)

2 ) .(99

-


4

-2019

-6 .(98

)

A

15

CT

-7

.(99

) -8

.(98

) -9

).

Remdesivir

.(99 7 .(

)

-10 Favipiravir Remdesivir

-11

Can FAH

).

Valve

.(99 -12 .(98

)

3

-13 .(99

) -14

.(98

)

10 -15

.(99

) -16 .(98) .

.

-17 .(

) -18

.(

)


5

-2019

-19 .(99 .(98

)

)

-20 -21 .(99

) -22

UV

.(

)

)

-23 .( 100

-24

Favipiravir

-25

. .(

) -26

.

Valve Can

-27 .(

). -28

.(

)

1000 -29

N95

/ -30

-31 ....


-2019

6

-32 . -33

PMS

-34

-35 -36 . -37 -38 -39 -40 -41

RNA/DNA

-42 -43 9 -44

-1

RNA DNA (VLP)

-2

ReNap Co

8

-3


7

-2019

-4 -5 :

: : -

ReNap

: -

Cell Tech

o o o

-46

CT

-47 8

-48 -49 -50


-2019

8

-51 -55 -56 -57 -58 -59 -60 -61 -62

CT

:

. .

...

-2 rtPCR


9

-2019

39 .

-3 -3-1 19:

19. . . : COVID 19

19

.1 .2 .3 .4 .5 )

19

.6 (.... 19

19

.7 .8 .9


10

-2019

.10 19

.11 .12

ICU

)

.13 (...

ICU

.14 .15 .16 -

)

.17 nested case-control

(.....

19

.18

-1 -2 -3 19

-4 -5 -6 -7 -8

:19 19

200 . .

. .


11

-2019

. .

. :

.

(nimadiran@gmail.com)

(Registry.behdasht.gov.ir)

/

-3-2 19

/ 19

.

)


12

-2019

:1

.(2 19

.

)

86

1

. . .

.

.

. .

.

.

17 7

3

) 90

1

. )

.(

. .

.

Global Research Collaboration for Infectious Disease Preparedness

(

GLOPID-R


13

-2019

http://nimad.ac.ir/content/200/COVID-19

.

(

) 1 19-

. Strengthening system, Improving the Public’s Health, National Public

.

Health Performance Standards Program

.

(

) :

.1 (

)

(

.2

)

.3

.

.4

:

.1 .(

) .2

.

.3 .

.4

.

(

) .5 . .


14

-2019

. .

-4 - SOLIDARITY 19

4 -

(

19

4

:(SOLIDARITY

)

-

(2 Remdesivir (1

. +

2500

.(2020

(1

(

+ 24)

(4

19

7)

(3

+

.

(2020

22)

.

30

405

11266

3500 (

) (Interim analysis) .

**

19**

) :

(

Remdesivir RR=0.95 (0.81-1.11, p=0.50; 301/2743 active vs 303/2708 control) Hydroxychloroquine RR=1.19 (0.89-1.59, p=0.23; 104/947 vs 84/906) Lopinavir RR=1.00 (0.79-1.25, p=0.97; 148/1399 vs 146/1372)


15

-2019

Interferon RR=1.16 (0.96-1.39, p=0.11; 243/2050 vs 216/2050)

596 2

SOLIDARITY

5257

. 3

2462 .(

99

1399

18

3

2462

) -

50

3

-

45

3

38

3

38 -

)

RCT

3

2 2

-

18

RCT

3

)

) -

32 31

https://covid19.trialstracker.net/ accessed November 08, 2020 https://www.covid-trials.org/ accessed November 08, 2020

-


16

-2019

2

25

2

24

2

21

2

18

2

17

2

14

2

12 -

2

11

2

-

11

2

-

10

-

1

9

1

8

1

8

1

8

1

8

1

8

1

7

1

7

1

7

1

7

1

5

1

5

1

4

1

-

4

1

-

4

-

1

4

1

4

1

3 -

1

1

-

12

2

1

-

-

3 3

-

3

-

-


17

1

-2019

3

1

-

3

PHR

)

)

-

(Remdesivir) (Tocilizumab)

(Quercetin)

+(

C

)

)

–

(IFN -1b)

(Sambucus nigra)

)

+

1-

(IFN -1a) 1-

)

( (

) ) + + +

(IVIG)

+ Zofa

(Salix)

(Artemisia)

+


18

-2019

) ) +

(

) )

)

(

)

Tenofovir ANIF1

Stopcivir

7MMF

– + + (

+

)

(.Ficus Carica L) +

+ D C

)

+

+

+

+

/

+

+

+

C

+

+

+ (

+

+

Oseltamivir

)

+

+

AB7

+

Cyclotide complex Myrtus® Active Hexose

+

+

AHCC)

+

(Correlated Compound ( ) (CURCUDEN)

+

/

+

/

+ + +

+

+ +

Anval SZ

1-

+

+

+

+ + +


19

) (Jollab)

-2019

/

(

1

+ +

– -

+ (

-

+

fennel - terminalia chebula

(

)

/

+

/

+

/

(Sofosbuvir+Ledipasvir)

)

(Sofosbuvir/Velpatasvir) Tranilast +Tranilast

+

Borage based

+

+

-

(HEP1)

(

Hep-S

) SNP

BCc1

colloide silver nasal spray 10ppm

(

8

) -

)

(

+

MAB98 Trachyspermum ammi Colchicum autumnale

(Phoenix dactylifera)

Nigella sativa

(tPA) (Edaravone)


20

-2019

Grapex

(prebiotic)

LactocareÂŽ

)

C

(

(DMSO)

)

0/2 -

N

-

(hymecromone)

C

+

A A, D, E, C, B D C B (25OHD) N

cold atmospheric plasma Convalescent Plasma

D3

-

zinc C D

) ( NK Placental stromal cell

3

(SVF)

-

GCSF

+C

(

-

+ +

)

(Ipecac)

. . MMR

(PPD)


21

-2019

(BER) «

» COVID-19

(PDT)

19

(Photobiomodulation)

( IRCT20160131026298N2) COVID-19 (IRCT20200325046860N1) 19:19-

PHR

(Oseltamivir

(IRCT (IRCT

(IRCT )

)

19: 19

(

(

19-

)

.5 .6

) 19 (IRCT

+

.4

D C

(IRCT

+

)

)

.1 .2 .3

.7

) 19

.8

(IRCT20200325046860N2) 19 -

(

)

.9

(IRCT20200318046812N1) )

.10


22

-2019

19

( IRCT

19

(

19

)

.11

(IRCT20200318046812N2)

(IRCT20080901001165N59) 19(IRCT20080901001165N48) 19 ) 19-

Zofa

(IRCT20080901001157N16)

(IRCT20080901001165N46) 19(IRCT20160131026298N5) 19-

(IRCT

(IRCT20080901001165N49) 19-

)

(IRCT20180129038542N1) 19(IRCT20191125045492N2) 19 (IRCT20171105037262N4) 19( ) anti-TNF(IRCT ) " + + " " + + + " (IRCT ) (IRCT20080901001165N51) covid19 ( ) 19(IRCT20080901001165N50) 19: 19 -

19 -

19-

(CoviGlobulin (CG

.12 .13 .14 .15 .16 .17 .18 .19 .20 .21 .22

Covid-19

"

+

.23

" +

" 19-

+

" .24 .25

(IRCT20080901001165N52) (IRCT20200508047346N1)

(IRCT20080901001165N58) 1919 1 ( ) (IRCT20080901001165N53,IRCT20200511047396N1) (N-acetyl cysteine)NAC (IRCT20080901001165N55) (IRCT20080901001165N60) 19(IRCT20080901001165N56)

.26 .27 .28 .29 .30 .31 .32


23

(IRCT

(IRCT20200509047373N1) 19 -

)

-2019

19-

(IRCT

) 19-

(IRCT

) 19-

19-

Cyclotide complex

(IRCT

) COVID-19

T

(

T

(

AB7

Glycyrrhizin

)

19-

(IRCT20160131026298N4) 19-

) COVID-19

(IRCT

19

19) 1399

(IRCT

(IRCT

1398 )

.34 .35

( IRCT20160131026298N5,IRCT20160131026298N6,IRCT20160131026298N3) ( IRCT20160131026298N6) 197(IRCT ) 19MMF 19Myrtus® (IRCT20080901001165N63) 192 (IRCT ) ) 19zinc C D (IRCT (IRCT ) 19-

(IRCT )

.33

( )

) 19

.36 .37 .38 .39 .40 .41 .42 .43 .44 .45 .46 .47 .48 .49 .50

(19-

) (19-

(IRCT20100228003449N28) COVID-19 (IRCT20100228003449N27) COVID-19

)

(Sofosbuvir/Daclatasvir) (IRCT20200128046294N2)

.1

.2 (IRCT20200322046833N1) 1399-1398 (IFN -1a) 1.3 (IFN -1b) 1.4


-2019

24

/

+

+

(IRCT20100228003449N29) COVID-19 COVID-2019

(IRCT20100228003449N30) COVID-19 / Remdesivir

(IRCT20171122037571N2)

-covid-19

(IRCT20120826010664N6) Placental stromal cell

COVID-19

(

)

(IRCT20200413047063N1)

.5 .6 .7 .8 .9 .10

(IRCT20180712040449N2) 2019 ( 44 1 ) .11 (IRCT20150914024017N1) .12 (19) 2019(IRCT20151113025025N3) 1399-1398 .13 (IRCT ) 19 Anti TNF.14 (IRCT20200312046749N1) -19(IRCT20200324046847N1) COVID 19 SEPTIMEB TM .15 COVID-19 ) .16 (IRCT20200404046947N1) :( :( COVID-19 ) .17 (IRCT20081027001411N3) COVID-) C .18 (IRCT20190917044805N2) :(19 : COVID-19 (25OHD) .19 (IRCT20200401046909N1,IRCT20200401046909N2) NK 21 .20 (IRCT20200417047113N1) Covid-19 ) .21 (IRCT 19.22 (IRCT20200411047025N1) : ( ) A, D, E, C, B .23 (IRCT20200319046819N1)


25

-2019

.24 COVID-19

(IRCT

(IRCT20200402046923N1)

) COVID- 19 COVID-19

(IRCT

)

(IRCT

19-

moderate intensity

(IRCT

) COVID-19

) 99

Covid 19

(IRCT

19-

(IRCT20200415047092N1)

)

:

COVID19

(IRCT20190717044241N2) COVID-19

Umifenovir

(IRCT20200523047550N1)

:(19-

)

) 2019

)

Covid-19

(IRCT

)

(IRCT

(IRCT

)

:( COVID-19

COVID-19

COVID-19

COVID-19

.32

.36

)

D

) 19-

.31

.35

Plasma Therapy Convalescent

(IRCT

.30

.34

) 99

(IRCT

19

)

( ) (IRCT

.27 .28 .29

.33

COVID-19

(IRCT

.25 .26

(IRCT ) (Actemra) Tocilizumab (IRCT20081027001411N4) :( COVID-19 ) (IRCT20200509047360N1)

.37 .38 .39 .40 .41 .42 .43

(IRCT20170211032494N3) 3 .44 ((IRCT20200511047399N1


26

-2019

(AHCC)

COVID-19

(IRCT

)

.45

:

– 19(IRCT

)

(IRCT

(IRCT20091201002804N12)

)

:

19-

.5 .6

Hydroxychloroquine

:

COVID-19

(IRCT20130917014693N10)

COVID-19

(

COVID-19

)

-

(

(IRCT20180923041093N5)

)

((IRCT20151227025726N15

(MSCs)

(IRCT20200421047150N1) (IRCT ) COVID-19 COVID-19

`

`

(IRCT

)

(IRCT

)

COVID-19

-1398

) 19

19

:COVID-19

.9

COVID-19

19-

(IRCT

.8

.12

Hydroxychloroquine

:

.7

.10 .11

(COVID-19 (IRCT20200711048076N1 COVID-19

.2 .3 .4

(COVID-19 (IRCT20151227025726N14

19

COVID-19

(IRCT20200328046882N1)

-

COVID-19

.1

(IRCT20200416047099N1 ) 2019

(IRCT20200428047228N1) 19(IRCT20200516047468N1) 1399 (IRCT20200428047228N2)

19(IRCT20200509047366N1)

.13 .14 .15 .16 .17 .18 .19


27

-2019

COVID-19

(IRCT20180923041093N6)

19-

(IRCT

(IRCT20170128032241N3) COVID-19

(IRCT

(IRCT

)

)

(IRCT

)

:ICU

CURCUDEN®

) 19-

Oseltamivir Umifenovir

19

(

)

COVOID-19

( )

(IRCT20200608047686N1)

19

(IRCT20200607047682N1) (IRCT20190131042569N5) (PDT)

19

(IRCT

)

(IRCT )

)

(19

ICU

:

+ (IRCT (IRCT

19+

(A ) (IRCT ) Covid-19 ) COVID-19 (IRCT ) COVID-19 ) 19-

)

) ) Covid- 19 (IRCT /

3

(B

(prebiotic)

COVID-

(IRCT

(IRCT

) 19-

:

«

) 19

(IRCT20200323046841N1)

(nCov-2019)

/

+

/

)

3

(IRCT20200325046859N1) (IRCT

)

.22 .23 .24 .25 .26 .27 .28

.30 .31 .32 .33 .34 .35 .36 .37 .38

.1

»

.2

IVIg

(

.21

.29

Open Label

(IRCT

.20

COVID-19

.3


28

-2019

(IRCT20081019001369N2) 2019 (Sambucus nigra)

2019

(IRCT20200404046933N1)

(IRCT20081019001369N3) 2019 (IRCT20081019001369N4) (19) 2019 (IRCT20200408046990N1)

(IRCT20200406046965N1)

:

–

(

)

(COVID-19)

COVID-19

(IRCT

(IRCT

)

) 19

(IRCT20200413047053N1) 19

(COVID-19 (IRCT20200409047007N1

: COVID-19

-

COVID-19

(IRCT20200408046990N2)

(IRCT20200405046958N1) colchicine

:

19-

(IRCT20170922036314N4) (IRCT20191228045924N1) (19) 2019 (19) 2019

COVID-19

(IRCT20200408046990N3) ) COVID-19

(IRCT20081019001369N5) (IRCT20160809029275N1) 19

(IRCT

4

) COVID-19

(IRCT20161206031256N3)

-

(

:

/ ;2019

+ (

) 2019

/

)

/

3

(IRCT

(IRCT20110726007117N11) COVID-19

(IRCT20081019001369N6) (19-

/

Lactocare

(IRCT20101020004976N6)

.6 .7 .8 .9 .10 .11 .12 .13 .14 .15 .16

:

(IRCT20150716023235N15) 19

.4 .5

.17 .18 .19 .20 .21 .22 .23 .24 .25 .26 .27


29

(

)

(IRCT20180103038199N3)

(COVID-19 (IRCT20200607047675N1 ( )

( )

-2019

COVID-19:

19-

-

)

19-

)

(IRCT20200325046859N2) :COVID-19

.31

(Ivermectin) .32 (IRCT20190602043787N3) ( ) (COVID-19) 19 .33 (IRCT20190406043175N3) COVID-19 .34 (IRCT ) : (COVID-19 (IRCT20200522047542N1 .35 .36 :( ) (IRCT20081019001369N7) (IRCT20200928048867N1 ) .37 3/2 – .38 (IRCT

:COVID-19 19-

A

(IRCT20170117032004N3) (IRCT20160310026998N10)

19-

(IRCT20160310026998N11)

2019 ICU

.29 .30

2

(IRCT20200610047722N1) COVID-19

.28

2019

(IRCT20200317046797N1) (IRCT20200324046851N1)

( )

Covid-19

(IRCT20200317046797N2) (IRCT20180802040678N4) 2019 (IRCT20200317046797N3)

((IRCT20140617018126N2

.1 .2 .3 .4 .5 .6 .7 .8 .9


-2019

30

covid-19

)

:COVID-19

(Tocilizumab) IL-6 (IRCT20200406046968N1) (IRCT (IRCT20200317046797N4)

19-

(IRCT20091012002582N21) COVID-19

.10 .11 .12 .13 .14

(IRCT20200406046968N2) ( ) COVID-19 (zifron) 1 .15 (IRCT20200406046968N3) (IRCT20190618043923N4) Covid19 .16 (HA330 (IRCT20200317046797N5 19.17 .18 (IRCT20200503047280N1) : – .19 (IRCT20200518047497N1) :COVID-19 .20 (IRCT ) 19: COVID-19 .21 (IRCT20090609002017N35) 19.22 (IRCT ) (IRCT20200522047545N1) :19 .23 (tPA) .24 (IRCT20200515047456N1) 19 19.25 (IRCT20200317046797N6) ( ) .26 (IRCT20200525047570N1) :COVID-19 .27 (IRCT20200518047497N2) 19 (SVF) .28 (IRCT ) / 19 .29 (IRCT20190312043030N2) 2019 .30 (IRCT )


31

-2019

19

(IRCT20091012002582N22)

.31

Verification of the efficacy of bromhexine hydrochloride in PREVENTION of COVID19 symptomatic .32 (disease. (IRCT20200818048444N1,IRCT20200317046797N7

(Tocilizumab)

COVID-19

) COVID-19

(IRCT20151227025726N13) (IRCT

-1 (IRCT

)

:

(IRCT

19

) (COVID-19)

COVID-19

(IRCT20150107020592N25)

COVID-19

(IRCT20150107020592N29) COVID-19

(IRCT20150107020592N24) COVID-19

.1 .2 .3 .4 .5 .6 .7 .8

(IRCT20151227025726N18,IRCT20150107020592N27) (IRCT20150107020592N23) 19: .9 :19 .10 (IRCT20190810044500N5) (IRCT ) COVID-19 .11 19 favipiravir .12 (IRCT20150107020592N30) COVID-19 Sitagliptin .13 (IRCT20200420047147N1) COVID19 Favipiravir .14 (IRCT20150107020592N26) .15 (IRCT20200209046427N1) COVID-19 (IRCT ) (COVID-19) .16 (IRCT20150107020592N22) .17 EVLW 19 Borage based .18 (IRCT20150107020592N28) 19.19 (IRCT20150725023332N3)


32

-2019

(COVID-19) (IRCT

(IRCT20151227025726N17)

) covid _19

.21 .22

low dose

(IMT)

(IRCT20200611047727N1)

(

COVID-19

.20

19

)

(IRCT20150303021315N19)

COVID 19

) COVID-19

: (IRCT

19

(IRCT20190727044343N1)

) 2019

(IRCT20131129015584N2) COVID-19 19 )

(

:ICU 1

19

(IRCT :2019

(

.24

(IRCT20180712040446N2) COVID-19 Photobiomodulation (PBM) .25 (IRCT20200616047799N1) (IRCT ) COVID-19 .26 COVID-19 (IVIG) .27 ((IRCT20151227025726N20) .28 (IRCT20191211045691N1) COVID-19 .29 (IRCT ) .30 (IRCT ICU COVID-19 .31 (IRCT20131115015405N4)

:19

(IRCT

.23

) (IRCT20200404046935N1) /

) 19-

( ( ) 19

:

COVID-19

+

(IRCT20190804044429N1) /

)

(IRCT20200403046926N1) ) (IRCT20200328046886N1)

.1 .2 .3 .4 .5 .6 .7 .8 .9


33

(IRCT

) COVID-19

-2019

Dimethyl Fumarate

COVID-19

(IRCT20190727044343N2)

19

(IRCT20200411047016N1) 19 (IRCT20131129015584N3) COVID-19 :COVID-19

)

(IRCT (IRCT

)

:

(

(IRCT20200411047030N1)

)

(

) (IRCT

:COVID-19

)

COVID-19

(IRCT

(

) 1399

(IRCT

) COVID-19 (IRCT ) COVID-19

)

)

1398

19

Stopcivir

(BER)

:19

(IRCT

COVID-19

(IRCT

) 19/(

/

(IRCT20200328046886N2)

)

/(

)

/

(IRCT )

/

COVID-19

/

) ( 19-

(IRCT20200913048708N1)

(

COVID-19

)

(IRCT20200316046792N1)

(MSCs)

(IRCT20140528017891N8) (IRCT20200410047009N1) COVID-19 COVID19

Outcome

(Ipecac) (IRCT

)

19

ARB ACEI

(IRCT

) 1398-99 2

(IRCT20140907019073N4) 19

.10 .11 .12 .13 .14 .15 .16 .17 .18 .19 .20 .21 .22 .23 .24 .25

.1 .2 .3 .4 .5 .6


34

-2019

:

(IRCT20161204031229N3) 19-

(IRCT20200318046812N1) COVID-19

(IRCT20190122042450N4)

:COVID 19

(IRCT

: COVID-19 " " "

/

+

+

+

) (IRCT20180725040596N2)

+ "

" +

" 19

(IRCT

:19

+ )

A

(IRCT20200405046951N1)

COVID-19

N-Acetyl Cysteine

:

(IRCT20200623047897N1)

(IRCT20200505047305N1) (IRCT (IRCT

:COVID-19

) 19 ) covid 19 (IRCT

)

(IRCT

(IRCT " (IRCT

) covid19

" " (

" (IRCT

.10 .11 .12

.13 .14

.15

.19 )

.20

(IRCT20200913048701N1)

:COVID-19

.9

COVID19

:

( )

.8

.16 .17 .18

COVID-19

2019

.7

) ) SNP

)

.21 .22 .23


35

19

(IRCT

-2019

.1

) :2019

(IRCT20200310046736N1)

(IRCT

) COVID-19

TNF-

TGF

IL-1, IL-6

IFN-

2019

(IRCT20200404046937N2)

2019

.2 .3 .4 .5

(IRCT20200404046937N1) COVID19

Tranilast (IRCT20200419047128N1)

Chloroquine Kaletra

.7

Tenofovir (COVID-19) (IRCT20200422047168N1)2019

COVID19 (IRCT20200419047128N2) Covid19

(IRCT

)

COVID19 (IRCT20200112046089N1) Ivermectin

COVID-19) 2019)

(19

.8 .9 .10 .11 .12

COVID-19 (IRCT20200519047510N1) Chloroquine Kaletra

.6

Chloroquine Kaletra (IRCT20200422047168N2)

)

.13 (IRCT20200404046937N3)

(

COVID-19:

)

.14

(IRCT20200616047792N1)

+

(SARS-covid-

19) (IRCT20200816048422N1) COVID-19: (IRCT20200404046937N4) (IRCT20190226042851N1)

COVID-19

)

2

.18 COVID-19 MMR .19 (IRCT20200802048266N1)

COVID-19:

19

.16 .17

colloide silver nasal spray 10ppm

(IRCT 19

.15

(IRCT20200404046937N5)

(IRCT20200730048253N1)

.20 .21


36

-2019

(IRCT

-

)

.1 .2

(IRCT20130616013690N7)

19

(IRCT

(IRCT20090701002113N2)

.3

)

.4 .5

COVID-19

(IRCT

)

)

COVID-19

(IRCT

(IRCT ) covid-19 (COVID-19 (IRCT20131215015805N2 :19

-

(IRCT

(IRCT

)

-

-

.1

(IRCT20200413047052N1)

COVID-19

)

8

.7 .8 .9

(IRCT20200508047345N1) COVID-19 . . .10 (IRCT20200411047019N1) COVID-19 .11 (IRCT ) covid-19 .12 (IRCT ) 1399 (IRCT ) 19 .13 (Jollab ) .14 ) : (COVID-19) .15 (IRCT ) COVID-19 .16 (IRCT ) COVID-19 Quercetin .17 (IRCT ) :covid-19 / .18

-

:

.6

:

COVID19

(IRCT

.2


37

(IRCT20200427047215N1) 19 (IRCT20180425039414N3) (COVID-19) SARS-cov2 (IRCT20200428047232N1) :

-2019

.3 .4 .5 .6

E C COVID19

-

:

(IRCT20121216011763N46)

.7

Covid-19

(IRCT

(IRCT20180425039414N2) covid 19 COVID-19 (

(IRCT20200428047229N1)

(IRCT20181208041886N1) COVID-19 : :(COVID-19)

(IRCT

(

(IRCT20200923048815N1)

)

(IRCT20200806048318N1) 19-

19-

(IRCT

19 :(covid-19

(IRCT

)

.10 .11 .12 .13 .14 .15

) (IRCT

)

.8 .9

)

19-

)

)

.16

) (IRCT

)

.17

-

.1

(IRCT20170611034452N11) (COVID 19) (IRCT20101219005416N2) (IRCT20180923041093N4) (COVID_19)

(COVID_19)

(IRCT20180923041093N3) COVID-19

(IRCT

) 99-98

.2

.3 .4 .5


38

-2019

.6

(IRCT20140911019125N6) 19 (IRCT20160313027033N2)

.7

19

.8

COVID-19 I

(

COVID-19

(IRCT

)

.9

(IRCT20200330046899N1)

19

.10

Ivermectin

(IRCT

(IRCT20101219005416N3) 19

(IRCT

)

)

.11

(COVID 19) (IRCT20161108030776N3) (IRCT20140911019125N8) 3 2

) 19-

- – 19

.1

Covid-19

-( ) )

(IRCT 3

)

(IRCT20180922041089N4)1399

(

)

) COVID-19

.2

(

COVID 19

(IRCT

.13 .14

-

.12

.3

PASI % 75

.4

(IRCT20200630047962N1)

)

(IRCT

)

(

)

.5

(

COVID 19

.6 .7

(IRCT20100228003449N31) COVID-19

:( COVID-19) 19 (IRCT20201015049030N1)

-

COVID-19 (IRCT20201004048922N1)

) COVID-19

:

19 (IRCT

.8 .9


39

-2019

(IRCT

)

( COVID-19 ):

(IRCT

)

.10 .11 .12

Covid-19

(IRCT

) 1399

.1

ICU

(IRCT

)

(IRCT20200404046934N1) COVID-19

19 19

(IRCT20160118026097N5) (IRCT20160118026097N4)

-

-

19-

(IRCT

(IRCT20160118026097N3)

(IRCT

A (IRCT20200314046774N1)

) 1399

Covid-19

) Covid-19

(

Covid-19 :

)

.2 .3 .4 .5 .6 .7 .8 .9

(IRCT20180513039641N2)

(IRCT

) 19

.10 .11 .12

fennel - terminalia chebula

(IRCT

)

(IRCT

)

19-

(IRCT20120215009014N353) (IRCT20200426047206N1) 19

.1 .2 .3

NBS

(IRCT20120215009014N354)

COVID-19:

(IRCT20120215009014N355)

.4

COVID-19:

.5

COVID-19: (IRCT20170117032025N7)

19-

(IRCT20200426047206N2)

.6 .7

COVID-19 : (IRCT20200426047206N3)


40

-2019

.8

COVID-19 (IRCT20200902048598N1)

(IRCT

)

19COVID-19 : (IRCT20200426047206N4)

(IRCT

) COVID-19

.11

COVID-19

(IRCT20151228025732N51) Convalescent Plasma

(IRCT20151228025732N53)

19 :

(IRCT20151228025732N52)

1000

-

(IRCT

»

)

(IRCT20200115046144N2)

(IRCT20171213037866N2) 19COVID-19

(IRCT20200402046917N1) (IRCT20160808029264N9)

(IRCT

19

:COVID-19 :COVID-19

.3

.5 .6 .7

Covid-19

(IRCT

.9

)

)

: (IRCT

(IRCT20200506047323N2) (IRCT20200506047323N1)

(IRCT20200509047364N1) COVID-19

.2

.8

COVID-19

19 -

.1

.4

GCSF

«

:

.9 .10

)

.10 .11

.1 .2 .3


41

-

: (IRCT20200514047445N1) 19-

COVID-

(

)

/

(IRCT20200506047323N3) :COVID-19 :COVID-19 (IRCT20200509047364N2) COVID-19

)

COVID-19

(IRCT

-2019

.4

19 (IRCT20200611047735N1) .5 .6 :19 .7 (IRCT20200506047323N4) .8 (IRCT20200506047323N5) .9 .10 (IRCT

) 19-

COVID-19

.1 .2

Sofosbuvir/Velpatasvir

Nigella sativa

”Trifluoprazine“

Trachyspermum ammi

(IRCT

) 19

(IRCT20130812014333N145) (MAB98) .3 Colchicum autumnale

” “Lithium Sofosbuvir-Daclatasvir”“ (IRCT20130812014333N147) COVID-19 ( ) FFP (IRCT )

.4 .5

COVID-

(IRCT20190624043993N3) (IRCT20190624043993N2)

(IRCT20200418047121N1) 19

) (COVID19)

COVID-19 COVID-19

50

.7 .8 .9

ARB ACEi

(IRCT

.6

(IRCT20160625028622N1) (IRCT20200505047318N1)

Covid-19

(IRCT20200408046987N1)

.1 .2 .3


42

-2019

19 ) COVID-19

(IRCT

50

) (IRCT

) 1399 (IRCT (IRCT

.4 .5 .6

covid-19

)

(IRCT

:Covid-19

) Covid-19

(IRCT ) ) 2019

(IRCT

(IRCT ) COVID-19 ) COVID-19

COVID-19

(IRCT

(IRCT20200504047298N2) 19 /

.1 .2 .3 .4

/

.5 .6

diphenhydramine compound

.7

19_

Covid-19

.7 .8

(IRCT20200504047298N1) (IRCT20200504047298N3)

(IRCT20200705048013N1) 19

pentoxifylline

-nCoV -2019

.8

.1 (IRCT20180610040049N3) (IRCT20151222025660N2) -nCoV -2019

(IRCT

/

(IRCT20200517047485N1) 1399

)

19 COVID-19

Tocilizumab (IRCT20200510047383N1) Host-Directed Therapy

(IRCT20180519039711N6) COVID-19

(IRCT

(IRCT

)

)

ivig COVID-19

Favipiravir

.2 .3 .4 .5 .6 .7 .8


43

(

-2019

)

+

(IRCT20200324046850N2)

.2 .3

(IRCT20200324046850N3) N

.1

D3

(IRCT20200324046850N1) COVID 19

C (IRCT20200324046850N5)

COVID-19 (IRCT20200326046868N1)

(IRCT

)

COVID-19

:COVID-19

/

(IRCT20200624047908N1) Grapex

(IRCT

)

COVID-19

(IRCT

(IRCT

)

) (1399)

)

) 19 (IRCT20180624040213N2)19-

.8

.1 .2 .3 .4 .5 .6

(IRCT

-1

COVID-19 (COVID-19) 2019

-1 (IRCT

) (1399)

(IRCT20201024049134N1)

(IRCT

) .COVID-19

(IRCT20200503047281N1) COVID-19

(IRCT

) 19 (IRCT20200825048514N1)

) 19 :19

.7 .8

COVID-19

)

.7

(COVID-19)

COVID-19

(IRCT

.5 .6

COVID19

(IRCT

.4

IRCT)

.1 .2 .3 .4 .5


44

-2019

)

19

(IRCT

(IRCT

) 19

.6 .7

(IRCT

) 19

(SARS-COV-2)

(IRCT20140305016852N4) (19-

19-

(IRCT20160706028815N5)

19

(IRCT

:COVID-19

)

3

(IRCT20151226025699N3)

(COVID-19)

)

(IRCT

(

.3 .4 .5

(IRCT20200705048011N1)

:COVID-19

.1 .2

)

)

.6 .7

.1

(IRCT20200405046960N2,IRCT20200405046960N1) COVID-19 COVID-19 (IRCT20200418047126N1) IRCT)

.3 .4

COVID-19 ( -COVID 19

Convalescent Plasma Therapy

:

(IRCT20150808023559N21) COVID-19

BCG

(IRCT

)

Covid-19 (IRCT20170716035126N4)

19-

(IRCT20150808023559N23)

COVID-19

:

(IRCT20160316027081N1) (IRCT20200404046948N1) covid-19

.2

.5 .6 .7

.1

.2


45

19

(IRCT

)

(IRCT

)

(IRCT

)

(IRCT

)

-2019

(IRCT20200406046963N1) covid19

19 19

"

19-

(IRCT20090304001739N3) COVID-19

(IRCT "

(IRCT20130428013151N2) COVID-19 (IRCT20160126026217N4) ) 19 A, D, E, C, B

(IRCT

:

(IRCT 19

(IRCT )

:19-

(IRCT20200416047104N1) covid 19

(IRCT

)

.4 .5

.5

covid-19

(IRCT

.3

.2 .3 .4

covid 19

1

)

.2

.1

COVID-19

)

.4 .5 .6 .7

.1

"

"

.3

)

– .1

Covid-19

(IRCT (IRCT 19

) ( )

( )

(

) .1399

(IRCT

)

)

19

.2 .3


46

-2019

:COVID-19

)

(IRCT

(IRCT20180114038350N3) (COVID 19) 2019 : COVID-19

(IRCT

(IRCT20190415043279N6) 19(IRCT ) 19-

:

COVID- 19

(IRCT20200408046992N1)

:19 -

(IRCT20200413047056N1)

) (IRCT

)

COVID-19

(IRCT ) 19 .COVID- 19

)

(

.4

.1 .2 .3 .4

.1 .2 .3 .4

.1

covid-19

(IRCT

)

COVID-19

(IRCT20200413047062N1)

19 19

(COVID 19 (IRCT20200501047259N1 (IRCT20200501047258N1) 19

(IRCT (IRCT

)

COVID-19

(IRCT20131112015390N5) 1399 (IRCT20181203041832N1) 19-

)

.2 .3 .4

.1 .2 .3 .4


47

-2019

) (IRCT20150303021315N17) ) Covid-19 " " "

/

+

-COVID

(haplo-identical) +

+

NK

(IRCT

+ "

" +

" 19

(IRCT

+

.1 .2 .3

) -

( )

19-

.1

(IRCT

)

:1399 -

COVID-19

(IRCT

) 1398-99

-

.2

( ) .3

(IRCT20201005048936N1) COVID-19

19

(IRCT

) 19

.1 .2 . (IRCT20081011001323N25)

(IRCT

) COVID-19

(

/

)

(IRCT20200418047116N1)

.3

.1

(IVIG) COVID-19:

19-

.2 (IRCT20140407017169N2)

:COVID-19

.3 (IRCT20200408046988N1)


48

-2019

(IRCT

0/2

)

.1

: covid-19

.2

(IRCT20200527047581N1)

)

: covid-19

(IRCT

+

(IRCT

.1

(IRCT20200324046852N1) (PPD) (IRCT20200414047070N1) 1399 -

19

)

.3

.2 .3

:19

.1 (IRCT20200725048199N1)

:19

(IFN -1b)

19

(IRCT

1-

.2

(IRCT ) (Phoenix dactylifera) )

(IRCT

.3

:

) (ARDS)

(IRCT20190418043307N1) COVID-19

(Ficus Carica L)

COVID-19

(IRCT

)

.1 .2 .3

19-

19-

(IRCT

(IRCT20120703010178N20)

) 19 (IRCT

)

.1 .2 .3


49

-2019

19-

(IRCT

) 1399

COVID-19

(IRCT

)

(IRCT -

19

)

.1 .2 .3

.1

120 19-

(IRCT20200831048568N1) 19 800 .2 (IRCT20200128046294N3) 19Sovodak .3 (IRCT ) 99 99

(IRCT20200325046860N1) COVID-19 COVID-19

(IRCT20200525047562N1)

(IRCT20120225009124N4)

.1

: 19

COVID-19

(IRCT20110907007511N4)

: COVID-19

(IRCT20200223046586N2) (DMSO) (IRCT20200727048217N1) COVID-19

19

(IRCT20200415047082N1) COVID-19

/

.1 .2

(IRCT20200412047042N1) 1399

.2

.1 .2

.1 .2


50

-2019

19

(IRCT20200513047426N1)

19

(IRCT20201003048904N1) 1399

(IRCT (IRCT

19

) 1399 ) COVID-19

.1 .2

.1 .2

.1

A

19

(IRCT20180520039738N2) ) .2 (IRCT20200415047089N1)

(

(IRCT

)

COVID-19 COVID-19

(IRCT20200416047099N2)

(safety) ) COVID-19

NK cell

(IRCT

) COVID-19

) ( (IRCT

)(

.1 .2

.1 .2

-

(IRCT

) COVID-19

(IRCT20200105046009N4) COVID-19

.1 .2


51

( )

)

-2019

.1

(IRCT20201003048905N1) 1399

ICU

COVID-19

(IRCT

.2

.1 (COVID19 (IRCT20200718048129N1 :COVID-19

"

" "(Sovodak (sofosbuvir + Daklatasvir)"

.2

(IRCT20200328046885N1)

COVID-19 (IRCT20200609047707N1)

COVID-19 (IRCT20200329046892N1)

(IRCT

)

(IRCT (IRCT

(IRCT

) ) 19 -

) 19 -

(IRCT

19-

-

(IRCT

) 19-

)

-

:


52

-2019

COVID-19

NK

(IRCT

)

(IMBSR)

(IRCT

)

:19

(IRCT20190831044653N5)19-

(IRCT20200405046953N1) (SOLIDARITY

19-

19

4

)

-

intermediate

(IRCT

)

x2 2

19-

(IRCT

) 1399

19-

Hep-S

BCc1

(IRCT20170731035423N2)

(IRCT

(IRCT

(IRCT

) (COVID-19)

)

) Covid-19

(IRCT20200426047212N1)19-

-


53

-2019

:19

(IRCT

)

COVID19

outcome (IRCT20200930048892N1)

Covid-19 (IRCT20180429039463N2)

:COVID-19

Celecoxib

(IRCT20200907048644N1)

-5 2019 . . . 19.

1 .


54

-2019

. .

48

.

-2 .

. 19.

. .

: (ethics.research.ac.ir)

-3


55

.

-2019

1397 .

.

. .

.

20

(ethics@behdasht.gov.ir)

:

-4

. ... .

-6


56

-2019

20 42 .

-7 5536 155 400

1399

18

194

99

18 9

-

9

293

9

274

9

259

9 8

-

252

-

245

-

)

184

8

150

7

138

7

-

136

7

-

133

7

127

7

120

7

-

-

119

6

-

114

6

-

105

6 6

-

401

9

4

68765

96 -

86

https://www.ncbi.nlm.nih.gov/research/coronavirus/, accessed on November 08, 2020

-


57

-

5

83

5

82

4

81

4

81

4

71 -

4

70

-

4

67 -

3

( )

3

66 65

-

3

57 -

3

56

3

56

3

56

3

53

3

51

3

-

49

3

-

44

3

44

3

43

2

-

41 -

2

39

2

39 36

-

-

36

2 2

-

62 -

3

2

-

62

3

2

-2019

(

34 -

33

2

-

28

2

-

25

2

-

25

2

-

24

-

2

21

-

2

20

-

2

20

-

2

18

)


58

-2019

2

17

2

17 -

2 -

2

-

16 16 -

15

1 «

1

»

-

15

1

14

1

14

-

1 1

13

1

12 )

-

12

1

-

12

1

-

11

1

-

11

1

-

11

1

-

11

1

1

11

1

11

1

10

1

10 -

1 1

10

-

-

-

13

-

-

-

-

-

10

5536

9

-

-8 (

)

19 .

(multicentral)

1399

20

SARS-COV-2

6 80


59

-2019

.

(multidisciplinary) http://nimad.ac.ir/content/202/COVID -19-Call

27

286 . 99

30

191399

19

.1

.2 SARS-Cov-2

N

nsp8 nsp3 S .3

SARS-CoV-2 COVID-19

TMPRSS2 ACE-2 .4

COVID-19 HLA HNA LIFT GAT GIFT SARS )

.5

19

(RDT)

.6 (COV2

19

.7 .8

SARS-CoV-2 COVID-19 SARS-CoV-2

.9 .10


-2019

60

19.11 .12

COVID-19

.13

19-

.14

SARS-CoV2 1399- 1398

.15

:

(Coronavirus (COVID-19

COVID-19 :

;1919-

: Covid-19

19-

.16 .17 .18 .19 .20

)

.21

.22

SARS-CoV-2

19RBD

Fc 19

Spike

.23 .24

.25 COVID-19 : 19-

.26 .27


61

-2019

19-

-1

Monitor Health Status to Identify Health Problems .1 .2 19 (IHR) International Health Regulation

.3

)

.4 .5

Diagnose and Investigate Health Problems and Health Hazards .6 .7 .8 Inform, Educate, and Empower People about Health Issues .9 .10 /

.11

.12 – .13

.14 .15 .16 .17 .18 .19 -

.20

Mobilize Community Partnerships to Identify and Solve Health Problems .21


62

-2019

.

.22 .23 .24 .25

Develop Policies and Plans that Support Individual and Statewide Health Efforts .26 .27 .28 .29

(...

)

)...

.30 .31

(

)

.32 .33 .34

19

.35 .36 .37 .38 .39

(

)

.40 .41

20

...

...

.42


63

-2019

.43

.44 .45 ...

.46 .47 .48 .49 .50 .51 Enforce laws .52 .53

Link People to Needed Personal Health Services and Assure the Provision of Health Care When Otherwise Unavailable .54 .55 . .56 .57 .58 .59 .60 .61 .62 .63 .64 .65 .66 .67 Assure a Competent Public and Personal Health Care Workforce .68 .69

ICU

.70 )

.71 .72


64

-2019

)

.73

.

.74 .75 .76

Evaluate Effectiveness, Accessibility, and Quality of Personal and Population-Based Health Services .77 ...

.78 .79 .80

.81 /

/

.82

/

whole university approach

.83 .84 .85

:

.86 :

–

.87 .88

Profile for IranWire

گزارش معاونت تحقیقات و فناوری وزارت بهداشت درباره اپیدمی ویروس کرونا  

براساس نسخه هفتم گزارش معاونت تحقیقات و فناوری وزارت بهداشت، درمان و آموزش پزشکی، منتشره در تاریخ ۲۰ آبان ۱۳۹۹، که نسخه ای از آن در اختیار «...

گزارش معاونت تحقیقات و فناوری وزارت بهداشت درباره اپیدمی ویروس کرونا  

براساس نسخه هفتم گزارش معاونت تحقیقات و فناوری وزارت بهداشت، درمان و آموزش پزشکی، منتشره در تاریخ ۲۰ آبان ۱۳۹۹، که نسخه ای از آن در اختیار «...

Profile for iranwire